OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

has great potential...50p on the cards.

You heard it here first!

Now seem to be for general distribution,

http://www.advisorybodies.doh.gov.uk/genetics/gtac/lentiviruses-1104.pdf

From the other place

Martin C-J - 11 Nov'04 - 15:34 - 13770 of 13785

I never usually post a response from an email but this time I will make an exception. I just received this a few seconds ago. I hope Alan Kingsman does not mind:

Dear Martin

Andrew Wood passed your e-mail to me. We have been aware of the information in the GTAC letter for some time. Let me reassure you that the vectors used in the study were not those that we use in the clinical products and in a vast range of animal experiments conducted over many months for our various products we have never seen a single adverse event caused by the vectors let alone any tumour induction.

Yours

Alan Kingsman

Rumours persist from the other place. Might be best to sit on the sidelines until resolved one way or the other - could be a bumpy ride short term. Medium-long term it's a quality company with some great technologies.

Still looking at this one,my be in soon.

buy in on weakness

I am thinking along those lines hlyeo98 , but a seem to be buying a lot of longs at the moment ..

I spoke to Alan Kingsman by phone and got the same information as Martin. Not only did he confirm the email response above, but mentioned that the "Academic Group" that ran into a problem with its mice were trying to do something quite different and were, in effect, using "problematic mice" to start with

My take on my conversation with Alan Kingsman yesterday, in clarifying the scope of the GTAC notice (see MJC email above also) was that he sounded supremely confident - imo

Oh well, drifting down again.

I'm waiting for 16p to buy some more.

Let the guys behind the scenes get on with it, sp will eventually reflect their work and achievements.

16 you say apple , now that would be nice ..

Now at 18p

Looking at the one year graph above, is there any analysts out there who can explain this one. As this is a high risk stock, is this why no pattern has emerged.

Down another 5.5%

Still hoping for 16p to buy some more.

what is going on ???? we need some good news please

It will come eventually but I hope we reach 16p first.

why is the 16p mark so magical???

Because it's just about as low at it could get before a big upswing. I have been trading this co for yrs and the patterns are easily assessed. We are at that time now I believe before some more newsflow and a price hike so if you haven't got onboard, nows a good time. This is very very good value - soon this co will be re-rated around the 50p level and the potential is enormous. My best Bio! A cure for cancer is not long away i'm hoping, i'm actually very confident that OXB is the next Glaxo.

robstuff wrote: i'm actually very confident that OXB is the next Glaxo.

Hey easy on, thats a pretty strong statement but I like your style.

I bought at 18.5p back in oct 04 but may dabble again at the magical 16p mark.

Come on OXB bring us some festive cheer.

I bet Glaxo didn't keep it's holders waiting this long!!